#Idiopathic Pulmonary Fibrosis market

[mordorintelligencemarketresearch]

Understanding the Idiopathic Pulmonary Fibrosis (IPF) Market: Growth, Challenges, and Innovations 

Idiopathic Pulmonary Fibrosis (IPF) is a progressive and life-threatening lung disease characterized by the scarring of lung tissue, making breathing increasingly difficult. The Idiopathic Pulmonary Fibrosis market is experiencing steady growth, driven by advancements in drug therapies, increased awareness, and funding for research and development. According to market research, the IPF market size is projected to reach USD 4.60 billion in 2024 and is expected to grow to USD 6.43 billion by 2029, with a CAGR of 6.95% over the forecast period (2024-2029). This expansion reflects the increasing demand for innovative treatments and improved diagnostic capabilities. 

Market Overview 

The rising incidence of IPF, particularly among people over 50, is a key factor driving the growth of the market. With improved diagnostics and a better understanding of the disease, healthcare providers are diagnosing IPF earlier, leading to a surge in demand for effective treatment options. 

Key Market Drivers: 

Growing Disease Prevalence: As the global population ages, the number of people diagnosed with IPF is rising, creating a growing need for advanced therapies. 

Advanced Diagnostic Tools: Innovations in imaging technologies and the use of biomarkers have enabled early and more accurate diagnoses, which is crucial for effective treatment. 

Drug Therapies and Approvals: The approval of antifibrotic drugs like pirfenidone and nintedanib has revolutionized IPF treatment, helping to slow the progression of the disease and improve patient outcomes. 

Challenges in the IPF Market 

Despite significant advancements, the IPF market still faces several hurdles: 

High Treatment Costs: The high cost of antifibrotic therapies can place a heavy financial burden on patients, particularly in regions with limited access to affordable healthcare. 

Limited Treatment Options: While existing treatments can slow disease progression, they are not curative, highlighting the unmet need for more effective drugs. 

Side Effects: Current medications often come with side effects, affecting patients' adherence to long-term treatment plans. Balancing efficacy with tolerability remains a key challenge for drug developers. 

Regional Insights 

North America holds the largest share of the Idiopathic Pulmonary Fibrosis market, thanks to advanced healthcare infrastructure and early adoption of new treatments. 

Europe follows closely behind, supported by growing government initiatives, robust healthcare systems, and increased R&D funding. 

The Asia-Pacific region is anticipated to witness rapid growth, fueled by rising healthcare expenditures and greater focus on the treatment of rare diseases such as IPF. 

Conclusion 

The Idiopathic Pulmonary Fibrosis market is positioned for continued growth, driven by innovations in diagnostics, drug therapies, and increased awareness of the disease. While challenges such as treatment costs and limited options persist, ongoing research and new drug development offer promising avenues for improvement. By 2029, with a projected market value of USD 6.43 billion, the industry is expected to make significant strides, potentially transforming the outlook for IPF patients around the world. 

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence https://www.mordorintelligence.com/industry-reports/idiopathic-pulmonary-fibrosis 

[mitalipingale]

https://zekond.com/read-blog/74895_idiopathic-pulmonary-fibrosis-market-analysis-size-share-and-forecast-2031.html

The Idiopathic Pulmonary Fibrosis Market in 2023 is US$ 3.82 billion, and is expected to reach US$ 6.67 billion by 2031 at a CAGR of 7.22%.

[bommagoni]

Idiopathic Pulmonary Fibrosis Market Size, Share, Trends 2030

[blogomonaco]

Global Idiopathic Pulmonary Fibrosis Market Is Estimated To Witness High Growth

The global Idiopathic Pulmonary Fibrosis Market is estimated to be valued at US$ 3,853.6 million in 2022 and is expected to exhibit a CAGR of 8.7% over the forecast period 2022-2030, as highlighted in a new report published by Coherent Market Insights.

A) Market Overview:

Idiopathic Pulmonary Fibrosis Market is a chronic and progressive lung disease characterized by scarring of lung tissues, which leads to difficulty in breathing and reduced lung function. The exact cause of IPF is unknown, hence the term "idiopathic", and there is currently no cure. The disease primarily affects individuals over the age of 50, and its prevalence is increasing due to aging population and exposure to environmental and occupational risk factors.

The mainstay of IPF treatment includes the use of antifibrotic drugs, such as pirfenidone and nintedanib, which slow down the progression of the disease and improve lung function. These drugs have shown significant efficacy in clinical trials and are considered as the standard of care for IPF. In addition, supportive care, such as oxygen therapy and pulmonary rehabilitation, is also provided to manage the symptoms and improve quality of life for IPF patients.

B) Market Dynamics:

The global Idiopathic Pulmonary Fibrosis Market is expected to be driven by the following factors:

1. Increasing R&D Activities: The pharmaceutical companies are actively engaged in the development of innovative therapies for the treatment of IPF. There are several pipeline drugs in various stages of clinical development that have shown promising results in early trials. For instance, Blade Therapeutics is developing a novel small molecule inhibitor for the treatment of fibrotic diseases, including IPF. Such advancements in drug development are expected to drive market growth.

2. Rising Prevalence of Respiratory Diseases: The prevalence of respiratory diseases, including IPF, is increasing globally. This can be attributed to factors such as air pollution, smoking, occupational exposures, and an aging population. According to estimates by the American Lung Association, around 200,000 individuals in the United States are affected by IPF, and it has a higher mortality rate than several types of cancer. The increasing prevalence of respiratory diseases is expected to drive the demand for IPF treatment.

C) Segment Analysis:

The Idiopathic Pulmonary Fibrosis Market can be segmented based on drug class and region. By drug class, antifibrotic drugs, such as pirfenidone and nintedanib, dominate the market. These drugs have been approved by regulatory authorities and have shown significant efficacy in slowing down the progression of IPF. The antifibrotic drugs segment is expected to dominate the market due to their established efficacy and increasing adoption.

D) PEST Analysis:

Political: The government regulations and policies surrounding healthcare, drug approval, and pricing can significantly impact the IPF market. A favorable regulatory landscape, such as streamlined drug approval processes, can boost market growth.

Economic: The economic factors, such as healthcare expenditure, reimbursement policies, and affordability of treatment, can influence the demand for IPF drugs. The availability of insurance coverage and affordable treatment options can drive market growth.

Social: The increasing awareness about respiratory diseases, advancements in diagnosis and treatment options, and the aging population are expected to drive the demand for IPF treatment.

Technological: Technological advancements in drug delivery systems, diagnostic tools, and drug discovery techniques can significantly impact the IPF market. The development of targeted therapies and personalized medicine approaches can improve treatment outcomes for IPF patients.

E) Key Takeaways:

- The global IPF market is expected to witness high growth, exhibiting a CAGR of 8.7% over the forecast period, due to increasing R&D activities and rising prevalence of respiratory diseases.

- North America is anticipated to be the fastest-growing and dominating region in the IPF market, owing to the high prevalence of IPF and well-established healthcare infrastructure.

- Key players operating in the global IPF market include Genentech, Inc., Boehringer Ingelheim International GmbH, AstraZeneca, and Bristol-Myers Squibb Company.

[sandyron456]

https://www.pickmemo.com/read-blog/89679

7th Nov 2022  Idiopathic Pulmonary Fibrosis (IPF) Treatment Market SWOT Analysis, Future Growth, Major Key Players, Opportunity and Forecast 2030

t is estimated that the global IPF treatment market is expected to register a CAGR of 12.3% during the forecast period of 2022 to 2027,

[rahulp3]

Bronchoscopes Market - Category-wise Insights By 2028

The Global Bronchoscopes Industry, valued at approximately US$ 501 Million in 2022, is set for an extraordinary surge, with projections indicating a 1.3X increase over the forecast period, according to the latest report by Future Market Insights (FMI). The market is anticipated to maintain a robust Compound Annual Growth Rate (CAGR) of 4.4% between 2022 and 2028, culminating in sales reaching US$ 647.7 million by the end of 2028.

Bronchoscopes, a significant segment of the global endoscopes market, are expected to represent around 4% of the market share by the close of 2021, as the overall endoscopes market is projected to reach a valuation of US$ 13.0 Billion in the same year.

The escalating prevalence of respiratory conditions such as idiopathic pulmonary fibrosis, pulmonary fibrosis, interstitial pneumonitis, occupational sarcoidosis, and pulmonary hemorrhage is driving an unprecedented demand for Bronchoscopes. This surge in demand not only underscores the critical need for advanced diagnostic and therapeutic tools but also presents lucrative opportunities for manufacturers to innovate and meet evolving healthcare challenges.

Request a Sample of this Report Now!https://www.futuremarketinsights.com/reports/sample/rep-gb-7965

[delveinsight12]

Idiopathic Pulmonary Fibrosis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB

DelveInsight’s “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Idiopathic Pulmonary Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Pulmonary Fibrosis Market Forecast

Recent Advancements in the Idiopathic Pulmonary Fibrosis Market:

In May 2023, Kinarus Therapeutics disclosed the execution of a strategic convertible loan agreement with ChaoDian (Hangzhou) Investment Management Co., Ltd. ("CDIM"), an investment firm based in Hangzhou City, China, for a CHF 1.5 million investment. This agreement lays the groundwork for discussions regarding the introduction, development, and commercialization of KIN001 for treating Idiopathic Pulmonary Fibrosis (IPF) in China. CDIM was introduced to Kinarus through Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Unique Group.

In April 2023, AGC Biologics announced the signing of a service agreement with The Jikei University in Japan. This agreement entails AGC Biologics undertaking a technology transfer and feasibility study for a drug product targeting the treatment of Idiopathic Pulmonary Fibrosis (IPF) at the CDMO's Cell and Gene Excellence center in Milan.

In February 2023, Insilico Medicine revealed that the US Food and Drug Administration (FDA) granted Orphan Drug Designation to INS018_055 for Idiopathic Pulmonary Fibrosis (IPF) treatment.

In February 2023, Arrowhead Pharmaceuticals Inc. announced the dosing of the first subjects in a Phase I/IIa clinical trial of ARO-MMP7, the company's investigational RNA interference (RNAi) therapeutic intended to reduce the expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF).

In February 2023, Daewoong Pharmaceutical of South Korea secured an exclusive licensing agreement with CS Pharmaceuticals for Bersiporocin, a first-in-class PRS inhibitor, in the Greater China region, including mainland China, Hong Kong, Taiwan, and Macau. This agreement enables CSP to license Bersiporocin for Idiopathic Pulmonary Fibrosis (IPF) and potentially other fibrotic indications for a total consideration of up to $336 million, including up to $76 million in upfront and development milestone payments and double-digit royalties on Net Sales.

In January 2023, Insilico Medicine reported positive topline results of safety, tolerability, and pharmacokinetics (PK) from the Phase 1 clinical trial of INS018_055, a potential first-in-class drug discovered by Insilico's end-to-end AI platform for Idiopathic Pulmonary Fibrosis (IPF).

In January 2023, Pliant Therapeutics unveiled 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast (PLN-74809) in patients with Idiopathic Pulmonary Fibrosis (IPF).

In December 2022, Vallon Pharmaceuticals announced the execution of a definitive agreement ("Merger Agreement") wherein GRI Bio would merge with a wholly-owned subsidiary of Vallon in an all-stock transaction ("Merger"). The combined entity is set to concentrate on advancing GRI Bio's innovative pipeline of NKT cell regulators for treating inflammatory, fibrotic, and autoimmune diseases. Post-merger, the combined company is anticipated to operate under the name "GRI Bio, Inc."

In July 2021, FibroGen revealed that FG-3019, their human monoclonal antibody targeting connective tissue growth factor (CTGF), had received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for idiopathic pulmonary fibrosis (IPF) treatment.

In June 2021, Redx Pharma announced the initiation of Phase I clinical trials for RXC007, an investigational oral therapy for idiopathic pulmonary fibrosis (IPF) and other fibrotic or scarring-related conditions, with the dosing of the first healthy volunteer.

In May 2021, ImmunoMet Therapeutics disclosed that the U.S. Food and Drug Administration (FDA) had granted fast track status to IM156, a prospective treatment for idiopathic pulmonary fibrosis (IPF).

In March 2021, MyMD Pharmaceuticals reported promising efficacy of their lead candidate, MYMD-1, in targeting the underlying causes of inflammation in idiopathic pulmonary fibrosis (IPF), along with its potential for treating various autoimmune and age-related disorders.

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report: 

The Idiopathic Pulmonary Fibrosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

The Idiopathic Pulmonary Fibrosis market size in seven major markets was USD 3,167 million in 2021

The total Idiopathic Pulmonary Fibrosis diagnosed prevalent cases in the 7MM was 194,878 cases in 2021 which is expected to rise, at a CAGR of 1.1% during the study period (2019–2032).

The expected launch of potential therapies may increase the Idiopathic Pulmonary Fibrosis market size in the coming years, assisted by an increase in the diagnosed prevalent population of Idiopathic Pulmonary Fibrosis.

Upcoming Idiopathic Pulmonary Fibrosis therapies such as Pamrevlumab, PRM-151 (pentraxin-2, RG6354), Tyvaso (treprostinil), BI 1015550, and others has the potential to create a significant positive shift in the Idiopathic Pulmonary Fibrosis market size.

The United States accounts for the largest Idiopathic Pulmonary Fibrosis market size, with approximately USD 2,321 million in 2021 and is expected to increase by 2032 at a Compound Annual Growth Rate (CAGR) of 6.3% for the study period (2019–2032).

The total Idiopathic Pulmonary Fibrosis Market Size in the EU-5 was USD 693 million in 2021, which is anticipated to grow at a CAGR of 7.8%.

Japan accounted for USD 153 million market share in 2021 i.e. 5% of the total Idiopathic Pulmonary Fibrosis Market Size in the 7MM.

Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB, and others

Key Idiopathic Pulmonary Fibrosis Therapies: ESBRIET (Pirfenidone), OFEV (Nintedanib), Pamrevlumab, PRM-151 (RG6354), Tyvaso (inhaled treprostinil), and others

The total Idiopathic Pulmonary Fibrosis diagnosed prevalent cases in the 7MM was 194,878 cases in 2021 which is expected to rise, at a CAGR of 1.1% during the study period (2019–2032).

The highest Idiopathic Pulmonary Fibrosis diagnosed prevalent cases was accounted for by the US in 2021, with 94,736 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population.

Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.

In the epidemiology model of DelveInsight, we have considered four age groups for the categorization of IPF i.e. 18–39 years, 40–59 years, 60–79 years, and >80 years. As per our analysis, the highest percentage of diagnosed prevalent cases was observed in age group 60–79, in all the 7MM countries.

As per DelveInsight’s analysis, the males are predominantly affected more highly with IPF than females. In 2021, there were 121,389 males and 73,488 females affected by IPF in the 7MM.

Japan accounted for 21,246 cases of total diagnosed prevalent cases of IPF in 2021 which are anticipated to rise by the end of 2032.

The Idiopathic Pulmonary Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Idiopathic Pulmonary Fibrosis pipeline products will significantly revolutionize the Idiopathic Pulmonary Fibrosis market dynamics.

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung condition marked by the thickening, stiffening, and scarring (fibrosis) of lung tissue, leading to progressive lung disease and shortness of breath. It is categorized as a type of idiopathic interstitial pneumonia, a group of lung disorders causing similar lung damage of unknown origin, also referred to as diffuse parenchymal lung diseases.

The primary symptom of IPF is breathlessness, particularly evident during physical exertion such as exercise. The exact cause of IPF remains unclear, with both familial and sporadic occurrences observed. Various factors, including immunological, environmental, and genetic elements, are believed to contribute to its development.

Idiopathic Pulmonary Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation:

The Idiopathic Pulmonary Fibrosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Idiopathic Pulmonary Fibrosis

Prevalent Cases of Idiopathic Pulmonary Fibrosis by severity

Gender-specific Prevalence of Idiopathic Pulmonary Fibrosis

Diagnosed Cases of Episodic and Chronic Idiopathic Pulmonary Fibrosis

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Epidemiology Forecast

Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Pulmonary Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Idiopathic Pulmonary Fibrosis Therapies

ESBRIET (Pirfenidone)

OFEV (Nintedanib)

Pamrevlumab

PRM-151 (RG6354)

Tyvaso (inhaled treprostinil)

Idiopathic Pulmonary Fibrosis Key Companies

FibroGen

Hoffmann-La Roche Ltd

United Therapeutics

Boehringer Ingelheim

Pliant Therapeutics, Inc.

Galecto Biotech

Horizon Therapeutics

CSL Behring

Kadmon Corporation

MediciNova

PureTech

Bristol-Myers Squibb

Nitto Denko Corporation

Vicore Pharma AB

Discover more about therapies set to grab major Idiopathic Pulmonary Fibrosis market share @ Idiopathic Pulmonary Fibrosis Treatment Landscape 

Scope of the Idiopathic Pulmonary Fibrosis Market Report

Study Period: 2019–2032

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech, Horizon Therapeutics, CSL Behring, Kadmon Corporation, MediciNova, PureTech, Bristol-Myers Squibb, Nitto Denko Corporation, Vicore Pharma AB, and others

Key Idiopathic Pulmonary Fibrosis Therapies: ESBRIET (Pirfenidone), OFEV (Nintedanib), Pamrevlumab, PRM-151 (RG6354), Tyvaso (inhaled treprostinil), and others

Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies

Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers 

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

Idiopathic Pulmonary Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement 

To know more about Idiopathic Pulmonary Fibrosis companies working in the treatment market, visit @ Idiopathic Pulmonary Fibrosis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Idiopathic Pulmonary Fibrosis Market Report Introduction

2. Executive Summary for Idiopathic Pulmonary Fibrosis

3. SWOT analysis of Idiopathic Pulmonary Fibrosis

4. Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

6. Idiopathic Pulmonary Fibrosis Disease Background and Overview

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis 

9. Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices

10. Idiopathic Pulmonary Fibrosis Unmet Needs

11. Idiopathic Pulmonary Fibrosis Emerging Therapies

12. Idiopathic Pulmonary Fibrosis Market Outlook

13. Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2019–2032)

14. Idiopathic Pulmonary Fibrosis Market Access and Reimbursement of Therapies

15. Idiopathic Pulmonary Fibrosis Market Drivers

16. Idiopathic Pulmonary Fibrosis Market Barriers

17.  Idiopathic Pulmonary Fibrosis Appendix

18. Idiopathic Pulmonary Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Latest Reports by DelveInsight

Adalimumab Biosimilar Market   | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Kritika Rehani

info@delveinsight.com 

+91-9650213330

[nidarsanafwr]

https://joyrulez.com/blogs/426663/Idiopathic-Pulmonary-Fibrosis-Market-Size-Overview-Share-and-Forecast-2031

Idiopathic Pulmonary Fibrosis Market Size, Overview, Share and Forecast 2031

[mitalipingale]

The Idiopathic Pulmonary Fibrosis Market in 2023 is US$ 3.82 billion, and is expected to reach US$ 6.67 billion by 2031 at a CAGR of 7.22%.

[universalnewspoint]

Idiopathic Pulmonary Fibrosis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics

http://dlvr.it/T1W2W7

[themarketinsights]

Pulmonary Fibrosis Drug Market May Set New Growth Story

Latest released the research study on Global Pulmonary Fibrosis Drug Market, offers a detailed overview of the factors influencing the global business scope. Pulmonary Fibrosis Drug Market research report shows the latest market insights, current situation analysis with upcoming trends and breakdown of the products and services. The report provides key statistics on the market status, size, share, growth factors of the Pulmonary Fibrosis Drug The study covers emerging player’s data, including: competitive landscape, sales, revenue and global market share of top manufacturers are Boehringer Ingelheim (Germany), MediciNova, Inc. (United States), Cipla Limited (India), Biogen (United States), F. Hoffmann-La Roche (Switzerland), Galapagos NV (Belgium), FibroGen, Inc. (United States), Merck KGaA (Germany), Bristol-Myers Squibb Company (United States), Prometic Life Sciences Inc. (Canada)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/177522-global-pulmonary-fibrosis-drug-market

Pulmonary Fibrosis Drug Market Definition:

Idiopathic pulmonary fibrosis (IPF) is a long-term lung condition that progressively worsens. The lungs stiffen as a result of scarring on the walls of the alveolar sacs (interstitium), which limits the lungs' capacity to absorb oxygen. This causes shortness of breath, which becomes worse as you exercise less and less. While there is no cure for IPF, medicines can assist with symptoms and reduce the disease's development. Because IPF patients' lung function and symptoms usually worsen with time, treatment is critical. Corticosteroids, azathioprine, and cyclophosphamide are the most often prescribed anti-inflammatory drugs. Colchicine, pirfenidone, and interferon-gamma (IFN-gamma) are all antifibrotic drugs that are becoming more popular.

Market Trend:

High Investment in Pharma R&D

Market Drivers:

Prevalence of Pulmonary Fibrosis Cases

Rising Geriatric Population

 

Market Opportunities:

Increasing Demand Across Emerging Regions

The Global Pulmonary Fibrosis Drug Market segments and Market Data Break Down are illuminated below:

by Drug (Pirfenidone, Nintedanib, Others), Form (Pills, Solutions, Tablets, Others), Distribution (Hospital Dispensaries, Retail Pharmacies, Third Party Online Sales)

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/177522-global-pulmonary-fibrosis-drug-market

Strategic Points Covered in Table of Content of Global Pulmonary Fibrosis Drug Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Pulmonary Fibrosis Drug market

Chapter 2: Exclusive Summary – the basic information of the Pulmonary Fibrosis Drug Market.

Chapter 3: Displayingthe Market Dynamics- Drivers, Trends and Challenges of the Pulmonary Fibrosis Drug

Chapter 4: Presenting the Pulmonary Fibrosis Drug Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: Displaying market size by Type, End User and Region 2015-2020

Chapter 6: Evaluating the leading manufacturers of the Pulmonary Fibrosis Drug market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: To evaluate the market by segments, by countries and by manufacturers with revenue share and sales by key countries (2021-2026).

Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

Finally, Pulmonary Fibrosis Drug Market is a valuable source of guidance for individuals and companies in decision framework.

Data Sources & Methodology The primary sources involves the industry experts from the Global Pulmonary Fibrosis Drug Market including the management organizations, processing organizations, analytics service providers of the industry’s value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine the future prospects.

In the extensive primary research process undertaken for this study, the primary sources – Postal Surveys, telephone, Online & Face-to-Face Survey were considered to obtain and verify both qualitative and quantitative aspects of this research study. When it comes to secondary sources Company's Annual reports, press Releases, Websites, Investor Presentation, Conference Call transcripts, Webinar, Journals, Regulators, National Customs and Industry Associations were given primary weight-age.

For Early Buyers | Get Up to 20% Discount on This Premium Report: https://www.advancemarketanalytics.com/request-discount/177522-global-pulmonary-fibrosis-drug-market

What benefits does AMA research study is going to provide?

Latest industry influencing trends and development scenario

Open up New Markets

To Seize powerful market opportunities

Key decision in planning and to further expand market share

Identify Key Business Segments, Market proposition & Gap Analysis

Assisting in allocating marketing investments

Definitively, this report will give you an unmistakable perspective on every single reality of the market without a need to allude to some other research report or an information source. Our report will give all of you the realities about the past, present, and eventual fate of the concerned Market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Southeast Asia.

Contact Us:

Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837

[mrudula01]

Key Industries & Applications in the Global Deep Learning Market

Over the years, deep learning has emerged as a transformative technology, revolutionizing the way various industries operate. Accordingly, the domain has become instrumental in the field of data analysis, predictive modeling, and process optimization. As per Inkwood Research, the global deep learning market is anticipated to grow with a CAGR of 39.67% during the forecast period 2023-2032.

In this blog, we will explore how major industries are leveraging the potential of deep learning in order to drive innovation and efficiency in their operations. We will also highlight real-world examples of successful deep learning applications in each of these industries.

1. Healthcare

Healthcare organizations of all specialties and types are becoming increasingly inclined toward how artificial intelligence (AI) can facilitate better patient care, while improving efficiencies and reducing costs. In this regard, the healthcare industry has been at the forefront of adopting deep learning for a wide range of applications, such as –

Medical Imaging: Deep learning algorithms have significantly improved the accuracy of medical image analysis. For instance, Aidoc (Israel), a leading provider of AI-powered radiology solutions, aims to improve the efficacy as well as accuracy of radiology diagnoses. The company’s platform utilizes deep learning algorithms in order to analyze medical images and aid radiologists in prioritizing and detecting critical findings.

Drug Discovery: Pharmaceutical companies are using deep learning to expedite drug discovery processes. Insilico Medicine (United States), for example, employs deep learning models to predict potential drug candidates, reducing the time and cost associated with developing new medications. The company’s early bet on deep learning is yielding significant results – a drug candidate discovered via its AI platform is now entering Phase II clinical trials for the treatment of idiopathic pulmonary fibrosis.

Disease Diagnosis: Deep learning is aiding in disease diagnosis through predictive modeling. PathAI (United States), for instance, utilizes deep learning-based AI solutions to assist pathologists in the detection, diagnosis, and prognosis of several cancer subtypes, thus improving the accuracy of diagnoses and patient outcomes.

2. Finance & Banking Services

The success of deep learning as a data processing technique has piqued the interest of the financial research community. Moreover, with the proliferation of Fintech over recent years, the use of deep learning in the finance & banking services industry has become highly prevalent across the following applications –

Fraud Detection: Banks and financial institutions deploy deep learning models to detect fraudulent activities in real time. Companies like Feedzai (Portugal) use deep learning algorithms to analyze transaction data and identify unusual patterns indicative of fraud. In July 2023, the company announced the launch of Railgun, a next-generation fraud detection engine, featuring advanced AI to secure millions from the surge in financial crime.

Algorithmic Trading: Hedge funds and trading firms leverage deep learning for algorithmic trading. Investors are utilizing deep learning models to evaluate and anticipate stock and foreign exchange markets, given the advantage of artificial intelligence.

Credit Scoring: Deep learning is transforming the credit scoring landscape. LenddoEFL (Singapore), for instance, creates, collects, and analyzes information from consent-based alternative data sources for an accurate understanding of creditworthiness. The company’s unique credit decisioning tools draw from large, diverse, and unstructured data sources through deep learning, artificial intelligence, and advanced modeling techniques.

3. Manufacturing

Here’s how the manufacturing industry benefits from deep learning in optimizing production processes and quality control –

Predictive Maintenance: Manufacturers use deep learning to predict equipment failures and schedule maintenance proactively. General Electric’s (United States) Predix platform employs deep learning to support innovative IoT solutions to help reduce downtime and maintenance costs.

Quality Control: Deep learning-based image recognition systems inspect products for defects on production lines. Real-time deep learning approaches are essential for automated industrial processes in product manufacturing, where vision-based systems effectively control the fabrication quality on the basis of specific structural designs.

Supply Chain Optimization: According to industry sources, deep learning models have the potential to generate between $1-2 trillion annually in supply chain management. In this regard, deep learning is used in the manufacturing sector to optimize supply chain operations by predicting demand patterns, enhancing inventory levels, and improving logistics planning.

Deep learning’s ability to process vast amounts of data and recognize complex patterns is transforming the way industries operate, making processes more efficient and enhancing customer experiences. As businesses strive to remain competitive in an increasingly data-driven world, leveraging deep learning and staying updated on its latest developments will be crucial for the overall growth of the global deep learning market.

FAQs:

What are the key components of a deep learning system?

A deep learning system typically comprises input data, a deep neural network architecture, loss functions, optimization algorithms, and labeled training data.

How does deep learning differ from traditional machine learning?

Deep learning, unlike traditional machine learning, eliminates the need for manual feature engineering by allowing models to learn and extract features automatically from data.

[thesunshinereporter]

Idiopathic Pulmonary Fibrosis (IPF) Market Poised for Phenomenal Growth During the Forecast Period (2023-32) – DelveInsight | Biogen, Celgene, Roche, Galapagos NV, FibroGen, MediciNova, Novartis

http://dlvr.it/SvdY5j